Abstract
Estimating Accumulated Dose in Image Guided Brachytherapy Treatment of Cervical Cancer
Highlights
Purpose/Objective(s): To evaluate the efficacy and toxicities of reirradiation for late (>10 years) vaginal recurrence in patients primarily treated by radiation therapy (RT) for cervical cancer Materials/Methods: This study reviewed cancer registry data of the department of radiation oncology in our hospital from 1974 to 2010
The criteria for patient eligibility included pathologically confirmed cervical cancer primarily treated with RT, >10 years disease-free status after RT, vaginal recurrence confirmed by histology and not suitable for surgical management, and use of radical dose RT as salvage treatment for vaginal recurrence
MR-guided brachytherapy (MRgBT) is becoming the new standard of care it is more demanding of resources and optimized processes will be of paramount importance in assuring widespread availability
Summary
Purpose/Objective(s): To evaluate the efficacy and toxicities of reirradiation for late (>10 years) vaginal recurrence in patients primarily treated by radiation therapy (RT) for cervical cancer Materials/Methods: This study reviewed cancer registry data of the department of radiation oncology in our hospital from 1974 to 2010. Materials/Methods: Twenty patients with cervical cancer who received external beam radiation therapy (EBRT: 45-50.4Gy in 1.8-2Gy fractions) and high dose rate MRgBT (28Gy in 4 fractions over two insertions) were included. All GEC-ESTRO OAR target doses (rectum
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
